Literature DB >> 26043774

Prediction of Significant Prostate Cancer at Prostate Biopsy and Per Core Detection Rate of Targeted and Systematic Biopsies Using Real-Time Shear Wave Elastography.

Katharina Boehm1, Lars Budäus, Pierre Tennstedt, Burkhard Beyer, Jonas Schiffmann, Alessandro Larcher, Kathrin Simonis, Markus Graefen, Dirk Beyersdorff, Georg Salomon.   

Abstract

INTRODUCTION: Prostate cancer (PCa) detection is accompanied by overdiagnosis and mischaracterization of PCa. Therefore, new imaging modalities like shear wave elastography (SWE) are required. AIM: The aim of this study was to evaluate per-core detection rates (DRs) of targeted biopsies and systematic biopsies and to test if SWE findings can predict presence of clinically significant PCa (csPCa) at biopsy. PATIENTS AND METHODS: Overall, 95 patients scheduled for prostate biopsy in our center underwent SWE. SWE findings were classified into suspicious or normal. Targeted biopsies were taken in up to 3 SWE-suspicious areas. csPCa was defined as the presence of Gleason pattern ≥4, level of prostate-specific antigen ≥10 ng/ml or >2 positive cores.
RESULTS: Overall DR for csPCa in our study cohort was 40%. Per-core DR for exclusively SWE-targeted cores versus systematic samples cores was 10.5 vs. 8.6% (p = 0.3). In the logistic regression models, individuals with suspicious SWE findings are at 6.4-fold higher risk of harboring csPCa (p = 0.03). Gain in predictive accuracy was 2.3% (0.82 vs. 0.84, p = 0.01).
CONCLUSIONS: Presence of suspicious SWE findings is an independent predictor of csPCa. Therefore, SWE may be helpful in selecting patients for biopsy. Nonetheless, per-core DR for SWE-targeted cores was not statistically significant higher than DR of systematic sampled cores. Therefore, additional systematic biopsy is mandatory.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26043774     DOI: 10.1159/000431233

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  6 in total

1.  Elevated hardness of peripheral gland on real-time elastography is an independent marker for high-risk prostate cancers.

Authors:  Qi Zhang; Jing Yao; Yehua Cai; Limin Zhang; Yishuo Wu; Jingyu Xiong; Jun Shi; Yuanyuan Wang; Yi Wang
Journal:  Radiol Med       Date:  2017-08-23       Impact factor: 3.469

2.  Stiffness of benign and malignant prostate tissue measured by shear-wave elastography: a preliminary study.

Authors:  Olivier Rouvière; Christelle Melodelima; Au Hoang Dinh; Flavie Bratan; Gaele Pagnoux; Thomas Sanzalone; Sébastien Crouzet; Marc Colombel; Florence Mège-Lechevallier; Rémi Souchon
Journal:  Eur Radiol       Date:  2016-08-23       Impact factor: 5.315

3.  Advanced ultrasound in the diagnosis of prostate cancer.

Authors:  Jean-Michel Correas; Ethan J Halpern; Richard G Barr; Sangeet Ghai; Jochen Walz; Sylvain Bodard; Charles Dariane; Jean de la Rosette
Journal:  World J Urol       Date:  2020-04-18       Impact factor: 4.226

Review 4.  Multiparametric ultrasound and micro-ultrasound in prostate cancer: a comprehensive review.

Authors:  Adriano Basso Dias; Ciara O'Brien; Jean-Michel Correas; Sangeet Ghai
Journal:  Br J Radiol       Date:  2021-11-09       Impact factor: 3.629

5.  Multiparametric ultrasound: evaluation of greyscale, shear wave elastography and contrast-enhanced ultrasound for prostate cancer detection and localization in correlation to radical prostatectomy specimens.

Authors:  Christophe K Mannaerts; Rogier R Wildeboer; Arnoud W Postema; Johanna Hagemann; Lars Budäus; Derya Tilki; Massimo Mischi; Hessel Wijkstra; Georg Salomon
Journal:  BMC Urol       Date:  2018-11-08       Impact factor: 2.264

6.  Role of Shear-Wave Elastography in Achilles Tendon in Psoriatic Arthritis and Its Correlation with Disease Severity Score, Psoriasis Area and Severity Index.

Authors:  Debajyoti Saha; Mahesh Prakash; Anindita Sinha; Tulika Singh; Sunil Dogra; Aman Sharma
Journal:  Indian J Radiol Imaging       Date:  2022-07-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.